MENSA, a Media Enriched with Newly Synthesized Antibodies, to Identify 1 SARS-CoV-2 Persistence and Latent Viral Reactivation in Long-COVID. 2

3 4

Natalie S. Haddad^{1,2}, Andrea Morrison-Porter^{1,2}, Hannah Quehl¹, Violeta Capric¹, Pedro A.

Lamothe¹, Fabliha Anam³, Martin C. Runnstrom^{1,4}, Alex D. Truong¹, Adviteeya N. Dixit¹, 5

Matthew C. Woodruff ^{3,5}, Anting Chen¹, Jiwon Park¹, Doan C. Nguyen¹, Ian Hentenaar¹, 6

Caroline Y. Kim¹, Shuya Kyu^{1,6}, Brandon Stewart¹, Elizabeth Wagman¹, Hannah Geoffroy¹, 7

Daniel Sanz, Kevin S. Cashman^{3,5}, Richard P. Ramonell^{1,7,8}, Monica Cabrera-Mora¹, David N. 8 Alter ⁶, John D. Roback⁶, Michael C. Horwath⁶, James B. O'Keefe⁹, Alexandra W. Dretler¹⁰, Ria

- 9 Gripaldo¹, Samantha M. Yeligar^{1,4} Ted Natoli¹¹, Viktoria Betin¹¹, Rahulkumar Patel^{1,3}, Kennedy 10
- 11
- Vela^{1,3}, Mindy Rodriguez Hernandez^{1,3}, Sabeena Usman^{1,3}, John Varghese^{1,3}, Anum Jalal^{1,3}, Saeyun Lee^{1,3}, Sang N. Le¹, R. Toby Amoss^{1,3}, John L. Daiss², Ignacio Sanz^{3,5}, F. Eun-Hyung 12 Lee^{1,5} 13
- 14

15 Affiliations:

- ¹Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, Department of Medicine, Emory 16 University, Atlanta, GA, 30322, USA. 17
- ² MicroB-plex Inc, Atlanta, GA, 30332, USA. 18
- ³Division of Rheumatology, Department of Medicine, Emory University, Atlanta, GA, 30322, 19 20 USA.
- ⁴ Department of Medicine, Atlanta Veterans Affairs Health Care System, Decatur, Georgia, 21 22 30033, USA
- ⁵Lowance Center for Human Immunology, Emory University, Atlanta, GA, 30322, USA. 23
- 24 ⁶Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, 30322, 25 USA.
- 26 ¹ Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine,
- University of Pittsburgh, Pittsburgh, PA, 15213, USA. 27
- ⁸ Asthma and Environmental Lung Health Institute, University of Pittsburgh Medical Center, 28 29 Pittsburgh, PA, 15213, USA.
- ⁹ Division of General Internal Medicine, Department of Medicine, Emory University School of 30 Medicine, Atlanta, GA, 30322, USA, 31
- 32 ¹⁰ Metro Infectious Disease Consultants, Decatur GA 30033, USA.
- ¹¹ImmuneID, Inc Biotechnology Research, Waltham, MA, 02451, USA. 33
- 34
- 35 Disclaimer: This work does not necessarily represent the views of the US Government or
- **Department of Veterans Affairs** 36
- 37
- Corresponding Author: 38
- 39 F. Eun-Hyung Lee, MD
- Division of Pulmonary, Allergy, & Critical Care & Sleep Medicine 40
- 41 Emory University
- 615 Michael Street, Suite 205 42
- Atlanta, GA 30322 43
- 404-712-2970 44
- 45 f.e.lee@emory.edu
- 46
- 47 **Running Title:**
- MENSA identifies viral drivers in PASC. 48

49 Author Contributions

FEL, JLD, and IS designed and supervised the study. NSH, FEL, JLD, SMY, AMP, and IS wrote
and/or edited the manuscript. NSH, FEL, and JLD developed and optimized the multiplex
immunoassays and MENSA technology used in this study. NSH, AMP, HQ, FA, VC, AC, and
MCW performed experiments and analyzed the data. AMP, HQ, FA, AC, JP, DCN, IH, CYK, SK,
BS, EW, HG, DS, KSC, MCM, and NSH collected and processed the samples. TN and VB
performed the PhIP-seq experiments. VC, RTA, PAL, MRH, MCR, ADT, AWD, RG, RP, KV, SU,

- 56 JV, AJ, SL, SNL, AND, JBO, and RPR recruited and managed patient enrollment. DNA, JDR,
- and MCH provided serum samples. All authors contributed to the manuscript revision, read, andapproved the submitted version.
- 59 60

61 Acknowledgments

62 This work was supported by National Institute of Allergy and Infectious Diseases, National

- 63 Institutes of Health 3P01AI125180-05S1, R01AI121252, R01AI 172254, P01A1078907,
- 64 U01AI045969, U19AI109962, U54CA260563, T32HL116271-07, and NIGMS 2T32GM095442,
- 65 NIH Department of Health and Human Services/Public Health Services: 5T32AI74492-14.

66 ABSTRACT

67

Post-acute sequelae of SARS-CoV-2 (SARS2) infection (PASC) is a heterogeneous condition, 68 but the main viral drivers are unknown. Here, we use MENSA. Media Enriched with Newly 69 70 Synthesized Antibodies, secreted exclusively from circulating human plasmablasts, to provide an immune snapshot that defines the underlying viral triggers. We provide proof-of-concept 71 72 testing that the MENSA technology can capture the new host immune response to accurately diagnose acute primary and breakthrough infections when known SARS2 virus or proteins are 73 74 present. It is also positive after vaccination when spike proteins elicit an acute immune 75 response. Applying the same principles for long-COVID patients, MENSA is positive for SARS2 76 in 40% of PASC vs none of the COVID recovered (CR) patients without any sequelae demonstrating ongoing SARS2 viral inflammation only in PASC. Additionally, in PASC patients, 77 MENSAs are also positive for Epstein-Barr Virus (EBV) in 37%, Human Cytomegalovirus (CMV) 78 in 23%, and herpes simplex virus 2 (HSV2) in 15% compared to 17%, 4%, and 4% in CR 79 80 controls respectively. Combined, a total of 60% of PASC patients have a positive MENSA for SARS2, EBV, CMV, and/or HSV2. MENSA offers a unique antibody snapshot to reveal the 81 82 underlying viral drivers in long-COVID thus demonstrating the persistence of SARS2 and

reactivation of viral herpes in 60% of PASC patients.

Graphical abstract



84 INTRODUCTION

85

In December 2019, the world was changed when the SARS-CoV-2 (SARS2) virus was identified 86 in Wuhan. China and rapidly spread throughout the world. The first U.S. case was identified in 87 88 January 2020¹, and by March 2020 the World Health Organization (WHO) had officially declared COVID-19 to be a global pandemic. By the end of 2020, there had been a total of 79 million 89 reported cases and over 1.7 million deaths globally². Vaccines and antiviral therapies allowed us 90 to combat this new global threat and emerge from this devastating pandemic^{3,4}. However, after 91 many in the US received the primary mRNA vaccines, a new Delta virus surged, followed by the 92 93 Omicron (B.1.1.529) variant by the end of 2021, which had increased transmissibility⁵.

94

In addition to new viral variant infections, some patients suffered from seguelae after the initial 95 96 acute infection. Long-COVID or post-acute sequelae of SARS-CoV-2 infection (PASC) is a condition described as ongoing, relapsing, or new symptoms present after the acute phase of 97 98 the infection. Incidence of PASC was notable in approximately 10% of patients after acute infection⁶. Definitions by the CDC used symptoms > 30 days after acute infection whereas the 99 100 WHO described continuation or development of new symptoms 3 months after the initial SARS2 infection, with symptoms lasting for at least 2 months with no other explanation⁷. The diversity of 101 symptoms and differences in plasma proteomics between inflammatory and guiescent PASC 102 subsets attest to the heterogeneity of long-COVID⁸. Additionally, many multiomic studies have 103 identified metabolic and inflammatory derangements such as decreased cortisol or serotonin 104 levels⁹⁻¹², complement dysregulation¹³, and alternations of cytotoxic T cell, atypical B cell, or 105 neutrophil signatures in PASC patients compared to adults who recovered from SARS2 without 106 sequelae^{9,10}. Some studies suggest that these inflammatory changes may be triggered by viral 107 persistence of SARS2 and/or reactivation of latent EBV^{10,14}. Interestingly, these studies used 108 109 viral PCR testing which is known to be less sensitive in the blood or requires ultrasensitive spike 110 antigen tests. Another study showed higher serum levels of EBV antibodies in PASC patients 111 (47%) compared to healthy adults (28%) but there was significant overlap between the two groups^{9,15} due to serum antibodies in response to a previous infection, confounding the 112 113 observation of new or ongoing immune responses.

114

In this study, we use a novel diagnostic platform whereby we capture antibodies secreted from 115 116 plasmablasts or newly-minted antibody secreted cells (ASC). This method can identify new or repeat infections despite elevated serum antibodies since these ASC appear in circulation 117 shortly after infection or vaccination, then rapidly disappear from the blood^{16-20 21,22}. By capturing 118 antibodies from these special ASC in a new matrix called Media Enriched with Newly 119 120 Synthesized Antibodies (MENSA), we provide a signature response from only the new illness. 121 MENSA antibodies often appear prior to seroconversion and differ from serum antibodies, which 122 confound results with the patient's entire historical microbial record. In prior studies, we have 123 successfully used MENSA to diagnose acute Lyme disease, *Clostridioides difficile*, Streptococcus pneumoniae, and deep bone/tissue infections with Staphylococcus aureus 19,23-124 ²⁷. In all, the novel MENSA assay can successfully diagnose repeat bacterial and viral infections 125 from a single blood sample even when serum antibody titers are extremely high, showing the 126 127 assay's exceptional ability to resolve complexity of antibody signals.

128

Here, we provide proof-of-concept testing that the MENSA technology can capture the new host
immune response to accurately diagnose acute primary and breakthrough infections when
known SARS2 virus or proteins are present. It is also positive after vaccination when spike
proteins elicit an acute immune response. Applying the same principles for long-COVID
patients, we use MENSA to identify SARS2, EBV, CMV, and/or HSV2 as the underlying viral
drivers in 60% of PASC patients. With a single blood sample, this novel diagnostic assay shows
persistence of SARS2 and/or reactivation of latent herpes viruses in long-COVID patients.

136 **RESULTS**

137

138 Patient enrollment. For the purpose of measuring serum and MENSA responses against SARS2 during infection and after vaccination, we enrolled a total of 241 adults between 2020 and 2024 139 140 at Emory University in Atlanta, GA and collected blood to generate the MENSA matrix and 141 serum samples (**Table 1**). During the first year of the pandemic in 2020, we enrolled 110 adults 142 with PCR- positive nasopharyngeal swabs (NPS) during their primary SARS2 infection. Fiftyfour adults were outpatients with mild/moderate (M/M) disease as defined by the NIH criteria²⁸. 143 144 and 56 adults had severe/critical (S/C) illness in the Intensive Care Units. From the 54 M/M 145 adults, we collected 59 blood samples: 16 during acute infection (within 30 days post-symptom 146 onset (DPSO)) and 43 during convalescence (60 DPSO). Five patients provided both acute and 147 convalescent samples. Of the 56 S/C patients, we had 60 samples: 40 provided acute illness 148 time points and 20 at convalescence. Four patients provided samples at both time points. These patients will be referred to as the primary SARS2 infection population. We also enrolled 60 149 150 healthy adults who had no known exposure to SARS2 and provided blood samples during the 151 initial lockdown period, between March and June 2020. This group is referred to as the healthy 152 controls without prior SARS2 exposure.

153

Serum and MENSA samples were collected from 11 vaccinated subjects who had no SARS2 154 155 infection prior to their primary two-dose mRNA vaccine series (Pfizer n=5, Moderna n=6). We 156 also enrolled 3 adults with Omicron breakthrough infections from December 2021-June 2022. 157 Finally, we enrolled 61 PASC patients from the Emory Long-COVID clinic from January 2021 to 158 February 2024 and compared against 25 COVID recovered patients without any sequelae (CR). Of note, some of the same subjects were enrolled in different groups. For example, some of the 159 healthy controls were later vaccinated and/or tested positive for breakthrough infections in the 4 160 years of the study; some patients after acute primary and/or breakthrough COVID infections 161 162 without any sequelae were also included in the CR groups.

163

SARS2 RBD and N antigen selection. SARS2 antigens were selected for measuring responses 164 165 to SARS2 infection and vaccination. Fluorescent bead assays were used as previously described for the SARS2 antigens with spike S1, S1 receptor binding domain (RBD), S1 N-166 terminal domain (NTD), S2, nucleocapsid (N), and ORF-3a²⁹. We measured the acute IgG 167 168 antibody responses against all six antigens in 56 adults with primary acute SARS2 infection 169 between 6-28 DPSO and compared them against 60 healthy control adults with no known SARS2 exposure. MENSA and serum antibody reactivity was significantly higher in the infected 170 groups than in the healthy control group for each of the six antigens (**Supplementary figure 1**). 171 172 Receiver operating characteristic (ROC) curves yielded Area Under the Curve (AUC) values of 173 ≥0.89 for the four spike-associated proteins, with MENSA anti-RBD demonstrating the highest 174 value, AUC=1.0 (Supplementary figure 2). To distinguish natural infection responses from vaccination responses, we examined the diagnostic potential of two non-spike proteins, N and 175 176 ORF3a. N vielded much higher signals in the infected groups and a slightly higher AUC value 177 than ORF3a. Therefore, we focus on anti-RBD and anti-N IgG for all subsequent analyses. 178

- Primary SARS2 infection responses in MENSA and serum. Primary infected patients were
 further divided based on the severity of their acute infections. During the acute stage of primary
 SARS2 infection, we observe a rise in both MENSA and serum anti-RBD IgG for M/M (69%,
 88%) and S/C (95%, 95%) patients (Fig. 1A,B). We see a similar rise in MENSA and serum
 anti-N IgG for M/M (69%, 88%) and S/C (80%, 95%) patients as well (Fig. 1C,D). During
 convalescence (60-360 DPSO, 2-12 months after), MENSA levels drop significantly while serum
 levels rise quickly and remain elevated for months to years especially for anti-RBD IgG (Fig. 1).
- The MENSA levels from S/C were higher than in M/M patients during the acute infection because of higher frequencies of circulating early-minted ASC as previously shown by flo
- 187 because of higher frequencies of circulating early-minted ASC as previously shown by flow

cytometry³⁰. Additionally, for S/C compared to MM patients, serum levels rise higher during the
 acute illness and remain elevated during convalescence, suggesting more ASC survived in
 other tissues such as the spleen, bone marrow, or mucosal sites. During convalescence, 87% of
 MENSAs become negative, but are overall slightly higher than pre-pandemic levels. In all,
 MENSA rises during acute infection and then rapidly falls to negative whereas serum titers rise
 and remain elevated.

194

205

216

195 Determining C_0 thresholds for positivity. Since the convalescent baseline MENSA negative values could be slightly higher than in pre-pandemic controls, we identify a subset of the 196 197 convalescent patients from Fig. 1 as COVID Recovered (CR) who had fully recovered with no 198 sequelae (N=19). CR MENSA samples were used as controls to calculate the MENSA C₀ using the average Net MFI plus 3 standard deviations. In contrast to MENSA, serum levels rise and 199 200 remain high indefinitely in both CR and PASC patients; therefore, the serum C₀ values are calculated using the average Net MFI plus 5 standard deviations of the 60 healthy controls prior 201 202 to SARS2 exposure. These calculated Net MFI C₀ values for MENSA (RBD: 570; N: 441) and serum (RBD: 1724; N: 682) are used to distinguish positive and negative samples in Figures 1-203 204 3, 5, and Supplementary figures 3, 4.

206 MENSA and serum from primary and booster mRNA vaccination. Similar to observations in primary acute SARS2 infections, adults receiving the COVID-19 vaccination, with no known 207 208 prior exposure, have positive MENSA IgG for SARS2 but only to RBD and not specific to N since only spike proteins are engineered in the mRNA vaccines (Fig. 2). This rise in MENSA 209 210 IgG to RBD 1-2 weeks after the first dose further increases to a higher peak after the second 211 dose. MENSA anti-RBD antibodies decline to negative levels prior to the third vaccine dose and 212 then increase again within a week after the third booster (Fig. 2A). Serum anti-RBD antibody levels increase after dose one and remain elevated throughout months to years (Fig. 2B). 213 214 Similar to serum titers, MENSA antibody levels to N are also negative providing accurate 215 responses to only the known proteins in the vaccines (Fig. 2C, D).

217 Longitudinal time-course of MENSA and serum after SARS2 infection and vaccination. Patients were recruited during the primary SARS2 infection or prior to the primary mRNA vaccine series. 218 219 Serial blood samples were collected for MENSA and serum at the first and each subsequent 220 SARS2 exposure events (infection and vaccination) to characterize the kinetics of the immune response during repeated exposure. In Fig. 3, we follow a 30-year-old Caucasian male subject 221 222 from his initial mild SARS2 infection in 2020, before and after three doses of the Pfizer mRNA COVID-19 vaccine in 2021, and finally during his breakthrough Omicron infection and recovery 223 in 2022. This subject's first draw was collected at 9 DPSO from his primary SARS2 infection in 224 225 early 2020. MENSA is positive for anti-RBD and anti-N IgG during the acute infection (Fig. 226 **3A,C**). The serum antibody titers are also weakly positive for anti-RBD and anti-N (**Fig. 3B,D**). 227 as expected in most primary M/M infections. By 80 DPSO, the serum levels have increased 228 further and remained elevated for several months while the MENSA levels rapidly decrease 229 back to baseline. Upon three vaccine doses, the MENSA anti-RBD antibody levels rise and fall 230 as expected whereas the serum antibodies to RBD remain positive from their previous infection 231 and demonstrate a modest increase. Again, MENSA to the N protein is negative since it is not a 232 component of the mRNA vaccine (Fig. 3C). However, serum anti-N levels remain weakly 233 positive for several months to years after initial infection and before declining (Fig. 3D). In 2022, two years after the primary SARS2 infection and 8 months since his last vaccine booster 234 vaccine, this subject had a PCR-confirmed Omicron breakthrough infection. Once again, the 235 236 MENSA for anti-RBD and anti-N increases together. As expected, serum anti-N titers rise 237 rapidly while the serum anti-RBD antibody levels, which were already high, remain elevated 238 (Fig. 3). Unlike serum, the kinetics of MENSA demonstrate a rapid rise after each SARS2 exposure, whether it is due to vaccination or infection, but then decline to baseline negative 239

240 values. MENSA is also highly discriminatory for spike (RBD) only after vaccination but shows a 241 combination of spike (RBD) and N antibody levels during acute infections. We present additional kinetics spanning several years from a 24-year-old Caucasian female through three doses of the 242 Moderna mRNA COVID-19 vaccine and an Omicron breakthrough infection (Supplementary 243 244 figure 3) and from a 35-year-old Asian male through four doses of the Moderna mRNA COVID-245 19 vaccine and an Omicron breakthrough infection (Supplementary figure 4). In all, during 246 SARS2 exposures from infection or vaccination, the MENSA antibody levels rise and then fall while serum titers rise after the primary exposure and stay elevated. 247

248

MENSA and serum in PASC vs COVID Recovered (CR). In addition to the 25 COVID recovered 249 250 patients with no subsequent sequelae, we enrolled 61 PASC patients from the Emory Long-251 COVID clinic from 2021 to 2024 with self-reported symptom questionnaires at enrollment (Fig. 252 4). We reconciled symptoms collected at enrollment and with a physician chart review and follow-up. The most common self-reported symptom in this PASC cohort was enduring fatigue in 253 97% of patients, followed by persistent shortness of breath (SOB) in 75% with some who 254 received new diagnoses of asthma or lung disease following their initial infection. Other common 255 256 symptoms included brain fog (67%), dizziness (52%), post-exertional malaise (47%), headache 257 (42%), chest and muscle pain (38% respectively), chronic cough (37%), depression/anxiety (37%), palpitations (32%), sleep disturbance (32%) joint pain/arthralgia (32%), and persistent 258 259 loss of taste or smell (30%) (Fig. 4). In addition to follow-up in the Long-COVID clinic, 35% 260 were referred for advanced neurology/neurocognitive evaluation and 58% for cardiac issues 261 with new diagnoses of tachycardia and/or postural orthostatic tachycardia syndrome (POTS) 262 (31%), arrhythmia/atrial fibrillation (19%), heart failure (11%), ongoing chest pain (11%), venous 263 reflux/vein compression by doppler ultrasound (11%), dysautonomia (8%) and 264 pericarditis/myocarditis (8%). Attempting to reconcile the 12 PASC symptom scores to better predict this long-COVID as recently reported in November 2023⁶, we calculated the average 265 266 PASC score of 11.8 at enrollment for the 60 patients. Total scores equal to or greater than 12 correlated with PASC patients at 6 months, while scores less than 12 were more likely to be 267 PASC indeterminate. 268

269

270 For the initial PASC experiment, we tested for only SARS2 antigens in MENSA and serum 271 samples prepared from the subset of 19 CR subjects mentioned above and 39 PASC patients 272 recruited during the first year of the Long-COVID clinic at Emory University December 2020-May 2021. For the CR group, fifteen of the samples were taken directly from the Figure 1 273 274 convalescent data while four of the patients donated additional follow-up samples. All patients were enrolled from day 60-279 DPSO after their initial acute infection and prior to any COVID-19 275 vaccination. Of the 39 PASC patients, 56% had initial M/M acute infections and 44% had initial 276 277 S/C acute infections. Of the 19 CR patients, 95% had M/M acute infections and 5% had S/C acute infections. In the 39 PASC patients, 33% still had positive MENSA for spike RBD after 60 278 279 DPSO compared to none in the CR group (Fig. 5A). Only 10% of PASC patients and none of 280 the CR patients had a positive MENSA for N (Fig. 5C). In serum, nearly all PASC (97%) and CR 281 (95%) patients had positive antibodies for RBD and N (Fig. 5B,D). One patient from each group 282 was negative for both antigens in their serum and MENSA.

283

<u>Human viral scan in MENSA of PASC and CR</u>. For discovery of other human virus reactivation
 in the MENSA samples, we compared MENSAs collected from 10 PASC patients in 2021 and
 three CR patients using the human PhIP-seq single-end DNA sequences that were aligned to a
 library of reference DNA sequences of 149,259 peptides tiling protein-coding sequences from all
 viruses with human hosts^{31,32}. Since it was early in the pandemic, the PhIP-seq was not
 optimized for SARS2. After quality control, we identified 227 peptides which were positive in
 MENSA in greater than three PASC patients and identified three additional major viruses, EBV,

CMV, and HSV2 (Fig. 6). Thus, a new PASC MENSA assay was developed using viral antigens
 from SARS2, EBV, CMV, and HSV2 (see methods).

MENSA for SARS2, EBV, CMV, and HSV2 in PASC and CR. In a cohort of 60 PASC patients 294 295 (39 patients in 2021 and 21 patients from 2022-2024), 21 CR patients (2020-2022), and 16 296 healthy adult controls (2020), we tested MENSA and serum for a combined SARS2, EBV, CMV, 297 and HSV2 IgG immunoassay. We had 23 samples from 21 CR patients since two individuals 298 suffered repeat SARS2 infections in 2020 and 2022. As expected, all healthy controls drawn prior to SARS2 exposure were negative for SARS2 IgG in both MENSA and serum (Fig. 7). 299 300 Only 2/16 (13%) were positive in the MENSA for any of the viruses tested (EBV) in the healthy 301 control group, whereas 14/16 (88%) were positive for EBV, CMV, and/or HSV2 in the serum. In the PASC vs CR groups, we show positive MENSA for SARS2 in 24/60 (40%) of PASC patients 302 and none in the CR (Fig. 7A). Nearly all PASC and CR patients are positive for the antibodies to 303 SARS2 in the serum (98% and 96%, respectively) (Fig. 7B). Interestingly, the lack of correlation 304 between MENSA and serum suggests they function as independent variables, although 305 frequencies of plasmablasts may be linked with rise in serum titers. 306

307

293

308 When examining the latent herpes viruses, MENSA reactivity was greater overall in the PASC 309 group than in the CR group (Fig. 7A). For EBV, more PASC patients had positive MENSA 310 samples 22/60 (37%) compared to CR subjects 4/23 (17%). A MENSA test was scored positive 311 if any one of the 3 antigens (EBNA1, VCA, and gB350) was positive. Nearly all individuals in the general population have been exposed to EBV and our results were consistent with this finding. 312 313 Here, EBV serologies are positive for 59/60 (98%) in the PASC group and all 23 CR samples. 314 MENSAs for CMV are positive in 14/60 (23%) of the PASC patients compared to 1/23 (4%) in 315 the CR group. Again, a test was scored positive if one of the two CMV antigens (gB or pentamer) was positive. Similar frequencies of positive CMV serology are notable in the PASC 316 317 patients 43/60 (72%) versus CR individuals 18/23 (78%). For HSV2, MENSA samples are 318 positive in 9/60 (15%) of the PASC patients, and 1/23 (4%) in the CR samples. The serum was 319 positive in 49/60 (82%) and 12/23 (52%) of the PASC and CR samples, respectively. Overall, MENSA assays are positive in 47% (28/60) of the PASC patients for EBV, CMV, and/or HSV2 320 321 whereas only 17% (4/23) are positive in the CR cohort. In all, we identify a positive MENSA in 322 36/60 (60%) PASC for any of the 4 viruses (SARS2, EBV, CMV, or HSV2) compared to 4/23 323 (17%) for the CR group. In conclusion, a positive MENSA for SARS2 in PASC patients 324 demonstrates ongoing new immune responses consistent with a reservoir for the persistence of SARS2 virus. Moreover, a positive MENSA for any of the 3 herpes viruses also demonstrates 325 reactivation of latent EBV, CMV, and HSV2 identifying underlying viral triggers in this condition. 326

327 328

329 DISCUSSION

330 331 Understanding the main viral drivers of the inflammatory and metabolic changes in patients with 332 long-COVID has been challenging. Multiomic studies provide a wealth of information but have not identified the underlying triggers of this chronic condition. Although suggestions of viral 333 334 persistence have been raised, it has been difficult to demonstrate ongoing reservoirs or 335 reactivation of the latent virus by PCR due to the limited sensitivity of the current tests. Thus, 336 detecting the pathogen has been challenging in patients with normal or even heightened immune responses. In this paper, we offer MENSA as a novel approach to identify the main viral 337 drivers of long-COVID. MENSA ascertains unique immune signatures by capturing the 338 339 antibodies from the circulating plasmablasts. These antibodies in the MENSA provide an immune snapshot that reveals the underlying drivers of the current illness. As proof of concept, 340 341 we show that with known exposure to SARS2 by infection or vaccination, MENSA from the blood is positive. Applying these same principles, in a cohort of 60 PASC patients of whom we 342

did not know the underlying cause, we show that 60% have a positive MENSA response against
 SARS2, EBV, CMV, and/or HSV2, thereby demonstrating ongoing reservoirs of SARS2 and/or
 reactivation of latent herpes viruses.

346

347 With first time infections, naive B cells are activated and undergo massive expansions through extrafollicular and germinal center reactions in the lymph nodes to form memory B cells and 348 349 newly-minted ASC that produce antibodies. Interestingly, the majority of these ASC die, but a few successfully migrate to the bone marrow or tissue sites where they can undergo further 350 maturation to become long-lived plasma cells (LLPC). Nearly all ASC circulating in blood are 351 newly generated and display markers of recent proliferation such as Ki67^{33,34,35}, unlike LLPC 352 353 which stop proliferating. Memory B cells persist over a lifetime and differentiate into plasmablasts when re-encountering the same antigens³⁵. During breakthrough or repeat 354 infections, newly-minted ASC mostly originate from memory B cells and circulate transiently in 355 the blood³⁵. Since MENSA measures antibodies only from these newly-minted ASC and not 356 357 from old LLPC, MENSA antibodies provide a unique antibody signature to reveal the cause of the present-day illness. We show that, during convalescence, the MENSA responses become 358 negative because memory B cells are no longer differentiating into ASC and released into the 359 360 blood. Thus, MENSA offers an immune snapshot to uncover the sources of the patient's 361 ailment.

362

363 Despite the high sensitivity of PCR testing in the nasopharyngeal swabs (NPS), blood PCR tests have limited utility for SARS2 and latent herpes viruses, such as EBV, CMV, and HSV2 due to 364 365 strong T cell responses that mediate rapid viral clearance. SARS2 antigen assays have been shown to identify the spike protein, but quantities are extremely low and require ultrasensitive 366 assays which carry a high risk of false positives¹⁴. Autopsies up to 230 days after acute SARS2 367 infection detected SARS2 RNA in multiple tissues such as the gut, central nervous system 368 (CNS), muscle, myocardium, and the respiratory tract³⁶ demonstrating viral reservoirs. Thus, 369 measuring the MENSA has advantages over pathogen detection by PCR amplification or protein 370 371 since MENSA is in the blood, agnostic to viral reservoir locations, and would not require invasive 372 tissue sampling. Since MENSA culminates from the total newly-minted ASC traveling in the 373 blood during acute illness, knowledge of the viral reservoir location is not necessary since the 374 MENSA reveals infections in deep-seated sites similar to a liquid biopsy.

375

Breakthrough or repeat infections can be diagnosed with serum assays, but they typically
require serial blood samples during acute infection and convalescence for comparison. Another
advantage of the MENSA over serum is that only a single blood sample during illness is needed.
The decline of MENSA to negative levels after infection or vaccination demonstrates its clinical
utility in measuring secondary or breakthrough infections.

381

Specificity of MENSA antibodies are also exact in that they can distinguish infection from vaccination based on spike and the nucleocapsid proteins in some patients. This specificity and sensitivity along with the kinetics make MENSA an ideal diagnostic platform to reveal viral triggers that were previously difficult to measure with just serum or PCR tests. The MENSA diagnostic would be the first of its kind to understand the main viral drivers of this chronic disease.

388

MENSA antibodies are expected to peak within days after exposure, and then quickly decline back to baseline within a month after the infection has resolved. Interestingly, CR MENSA does not revert to pre-pandemic baseline levels and these mechanisms are not clear. Perhaps nonspecific plasma antibody binding to monocytes in the MENSA cultures may be the reason and will require more studies. Another possibility is low-level bystander responses which have been suggested³⁵ to explain the difference between pre- and post-pandemic samples. Interestingly,

- even when using the post-pandemic MENSA samples as controls, 60% of the PASC patients
 have higher SARS2, EBV, CMV, and HSV2 responses in the MENSA.
- 397

Autoantigen triggers have also been implicated in PASC patients, and so we tested MENSA 398 399 from a limited number of PASC patients for autoantigens using the PhIP-seq human peptidome 400 library which consists of 605,656 peptides tiling protein-coding sequences, splice variants, noncoding open reading frames, and endogenous retroviral sequences in the human genome ^{37,38}. 401 402 No differences were observed between the PASC and CR MENSA against the human 403 peptidome (our unpublished results). However, a larger number of patients using the 3-D 404 conformational epitopes of the human proteome may be needed to definitively rule out MENSA 405 responses to autoantigens. Since the original PhIP-seq assays used linear viral peptides, we may also consider a panel of 3-D conformational epitopes to identify important unique immune 406 407 signatures for viruses that infect humans to ensure comprehensive testing for other viruses.

408

There are several limitations of this study. One is that we do not have longitudinal samples from the PASC patients and thus, it is unclear how consistent the MENSA responses are in the patients with chronic illness over time. Second, large clinical trials are needed to evaluate responses to anti-viral therapies in MENSA positive patients identified with SARS2 persistence

and reactivation of EBV, CMV, or HSV2 infections. Finally, the utility of MENSA may be

- 414 challenging in immunocompromised patients since the MENSA requires B cell activation to form 415 new ASC.
- 416

417 The real-time immune snapshots provided by MENSA may be leveraged to inform therapeutic 418 strategies and successful treatment of chronically ill PASC patients. Whether MENSA can also 419 be useful to identify persistence of viral reservoirs in other chronic illnesses such as multiple 420 sclerosis, HIV, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and other 421 infections with post-sequelae are yet to be determined. For example, EBV was recently implicated in multiple sclerosis³⁹. Interestingly, infection with SARS2 is associated with 422 increased susceptibility and severity of neurodegenerative disorders, such as Alzheimer's 423 disease. Parkinson's disease, and dementia but interpreting these correlations has been difficult 424 ⁴⁰⁻⁴². If MENSA can lead to early diagnosis of these chronic neurodegenerative disorders or help 425 426 identify the cause of these disease flares, perhaps treatments may prove more effective in 427 preventing progression and severity of these pathological conditions.

428

PASC can include symptoms, such as dyspnea, fatigue, and depression⁴³, and serious clinical
indications, such as cardiovascular disease or diabetes^{44,45}. Recent studies also suggest
increased risk for autoimmune inflammatory rheumatic diseases in PASC and CR patients⁴⁶⁻⁴⁸.
Future clinical trials are necessary to perform proof-of-concept studies where MENSA data
could be used to inform treatment modalities for mitigating symptoms associated with SARS2
viral persistence, reactivation of viruses, reactivation of viruses in other chronic illnesses, or
early activation of other chronic illnesses.

436

In summary, MENSA is a novel immune diagnostic which captures unique signatures of the
early-minted ASC in the blood to reveal the cause of illness. In chronic conditions such as PASC
where serum antibody titers are high, MENSA is an independent matrix that identifies
persistence of SARS2 viruses or antigens and can also recognize the reactivation of latent
herpes viruses, such as EBV, CMV, and HSV2 in 60% of patients. This host immune snapshot
reveals the fundamental drivers of viral persistence and reactivation in this chronic disease.

443 Declaration of Potential Conflicts of Interest

FEL is the founder of MicroB-plex, Inc. and serves on the scientific board of Be Biopharma, is a 444 recipient of grants from the BMGF and Genentech, Inc., and has served as a consultant for 445 Astra Zeneca. NSH and AMP were scientists at MicroB-plex, Inc., Atlanta, GA and JLD is a 446 447 scientist at MicroB-plex, Inc., Atlanta, GA. IS has consulted for GSK, Pfizer, Kayverna, Johnson 448 & Johnson, Celgene, Bristol Myer Squibb, and Visterra. FEL, DN, and IS are inventors of the patents concerning the plasma cell survival media related to this work (issued 9/21/21, US 449 11,124766 B2 PCT/US2016/036650; and issued 9/21/21, US 11,125757 B2). FEL & JLD are 450 inventors of MENSA patent U.S. Patent No. 10,247,729. April 2, 2019. FEL, NSH, JLD, & IS are 451 inventors of the MENSA PASC diagnostic provisional patent, March 28, 2024. All other authors 452

453 have declared that no conflict of interest exists.

454 **METHODS online**

455

456 Subject Enrollment and Sample Collection

Patient enrollment. We enrolled 241 adults between 2020 and 2024 at Emory University in 457 458 Atlanta, GA and collected blood to generate the MENSA matrix and serum samples (Table 1). In 2020, we enrolled 110 adults with PCR-positive NPS during their primary SAR2 infection. Fifty-459 four adults were outpatients with mild/moderate (M/M) disease as defined by the NIH criteria²⁸, 460 and 56 adults had severe/critical (S/C) illness in the Intensive Care Units. We also enrolled 60 461 462 healthy adults with no known exposure to SARS2 early during the pandemic with blood samples 463 collected between March and June 2020 during the initial lockdown as the healthy adult controls 464 without prior SARS2 exposure. Eleven vaccinated subjects who had no prior SARS2 infection were enrolled before and during their primary two-dose mRNA vaccine series (Pfizer n=5. 465 466 Moderna n=6) and drawn again before and after their third booster dose. We also enrolled 3 467 adults experiencing Omicron breakthrough infections between December 2021 and June 2022. 468

- Finally, we enrolled 61 long-COVID or PASC patients from the Emory Long-COVID Clinic which 469 was started in January 2021 until February 2024 (Fig. 4). Initially, 40 patients were enrolled in 470 471 2021 (Figs. 5, 6, 7) and an additional 21 patients were enrolled in 2022-2024 (Fig. 7). All patients filled patient-reported symptom guestionnaires. Samples from nine of the initial 39 472 473 PASC patients from Fig. 5 and one additional PASC patient recruited in 2021 were sent to 474 Immune ID for PhIP-seq analysis along with samples from three COVID Recovered patients (1/3 CR from initial convalescent cohort in Fig 1; 2/3 new CR patients). All blood samples were 475 476 collected under the Emory University Institutional Review Board-approved protocols.
- 477

478 **MENSA Preparation:** Medium enriched for newly synthesized antibodies (MENSA) was 479 generated by isolating, washing, and culturing antibody-secreting cells (ASC)-containing 480 peripheral blood mono-nuclear cells (PBMC) from blood using a modified procedure previously described ²³. Peripheral blood samples were collected in sodium heparin tubes and PBMC were 481 482 isolated by centrifugation (1,000 ×g; 10 min) using Lymphocyte Separation Media (Corning) and 483 Leucosep tubes (Greiner Bio-One). Five washes with RPMI-1640 (Corning) were performed to 484 remove serum immunoglobulins (800 x g; 5 min) with erythrocyte lysis (3 mL; 3 min), and harvested PBMCs were cultured at 10⁶ cells/mL in R10 Medium (RPMI-1640, 10% Sigma FBS, 485 486 1% Gibco Antibiotic/Anti-mycotic) for 24 h at 37° C and 5% CO₂. After incubation, the cell 487 suspension was centrifuged (800 ×g; 5 min), and the supernatant (MENSA) was separated from 488 the PBMC pellet, aliquoted, and stored at -80°C for testing.

Serum Preparation: Whole blood was collected and incubated at room temperature for at least
30 minutes. The clot was discarded, and the remaining serum supernatant was centrifuged
(800xg; 10 min), aliquoted and stored at -80 °C for testing.

Antigen Selection and Multiplex Immunoassays: Antigens of interest were selected from
 literature, coupled to Luminex MagPlex Microspheres of spectrally distinct regions via
 carbodiimide coupling, and tested for antigen specific IgG reactivity against patient samples as
 previously described ²⁹.

498

489

493

<u>SARS2 antigens</u>: SARS-CoV-2 Spike S1 Receptor Binding Domain (RBD; catalog no. Z03483;
 expressed in HEK293 cells) and Nucleocapsid protein (N; catalog no. Z03480; expressed in
 Escherichia coli), were purchased from GenScript. S1 (catalog no. S1N-C52H3; HEK293), S2
 (catalog no. S2N-C52H5; HEK293) and S1 N-terminal domain (NTD; catalog no. S1D-C52H6;
 HEK293) were purchased from ACROBiosystems. The C-terminus sequence of ORF3a
 (Accession: QHD43417.1, amino acids 134-275 plus N-terminal His6-Tag) was sent to
 Genscript for custom protein expression in E. coli. Each protein was expressed with an N-

- terminal His6-Tag to facilitate purification, at least 90% pure, and appeared as a predominantsingle band on SDS-PAGE analysis.
- 508

EBV, CMV, and HSV2 antigens: EBV, CMV, and HSV2 antigens were carefully selected for 509 antigenicity based on previous reports⁴⁹⁻⁵⁴. The following proteins were used: EBV EBNA1 510 protein from Abcam (produced in E. coli, N-Terminus His Tag, CAT#ab138345); EBV VCA p18 511 512 from RayBiotech (produced in E. coli, CAT#227-20127); EBV gp350 protein from 513 AcroBiosystems (produced in HEK293 cells, His Tag, MALS verified, CAT#GP0-E52H6); CMV 514 glycoprotein B from AcroBiosystems (strain AD169, expressed from HEK293 cells, His Tag, 515 MALS verified, CAT#CMB-V52H4); CMV gH pentamer complex, consisting of gH, gL, UL128, 516 UL130 and UL131A proteins, produced in mammalian HEK293 cells from The Native Antigen Company (CAT#CMV-PENT); HSV2 envelope glycoprotein D from AcroBiosystems (gD, 517 expressed HEK293 cells, His Tag, MALS verified, CAT#GLD-V52H4). 518

519

520 Serum and MENSA assays for SARS2 and other viruses: Serum samples were tested at 1:500 521 dilution in assay buffer (1XPBS, 1% BSA) while MENSA samples were tested neat with no 522 dilution. Results were analyzed on a Luminex FLEXMAP 3D instrument. Median fluorescent 523 intensity (MFI) using phycoerythrin-conjugated detection antibodies (Goat Anti-Human IgG-PE, Southern Biotech cat. #2040-09) was measured for each sample using the Luminex xPONENT 524 525 software on Enhanced PMT setting. The background value of assay buffer or R10 media was 526 subtracted from the serum or MENSA results, respectively, to obtain MFI minus background (Net MFI). All samples were tested in duplicate and the average of the two results were used for 527 528 analysis. In the initial SARS2 assay, all SARS2 protein bound microparticles were run together 529 as a six-bead SARS2 solution. Serum C₀ values of positivity were calculated as the average 530 plus five standard deviations of the Healthy Control population (N=60) for each antigen (RBD: 1724; N: 682). MENSA C₀ positivity values were calculated as the average plus three standard 531 532 deviations of the Contemporary Controls (COVID Recovered N=19 (CR) group described above) for each antigen (RBD: 570; N: 441). 533

534 Later. the assay was modified to contain only RBD, N, S1, and S2 from SARS2 (NTD and 535 ORF3a dropped) and also included the addition of all EBV, CMV, and HSV2 antigens, for a 536 combined multi viral 10-antigen bead assay. All new Cos were calculated based on the new 537 538 assay data in Figure 7. MENSA C₀s were calculated as the average plus three standard deviations of 22/23 CR samples (RBD: 404: N: 266: EBNA1: 475: VCA: 426: gp350: 523: gB: 539 298; Pentamer: 455; gD: 308). One sample was excluded from the MENSA C₀ calculation due 540 to multiple antigen reactivity measuring greater than 10 times the median value of the entire 541 group. SARS2 Serum C₀ was calculated as the average plus three standard deviations of the 16 542 543 Healthy Donor samples collected prior to SARS2 exposure. Since the majority of the population is expected to be positive for EBV, CMV, and/or HSV2 antibodies in their serum, we obtained 544 545 de-identified clinically confirmed negative sera from the Emory clinical laboratory. For each 546 virus, three confirmed negative serum samples were used. The average Net MFI plus three 547 standard deviations was calculated for each antigen and used as the C_0 threshold for positivity (RBD: 410; N: 564; EBNA1: 3,578; VCA: 593; gp350: 228; gB: 778; Pentamer: 769; gD: 858). 548

549

Phage immunoprecipitation sequencing and analysis. We constructed a custom T7 550 551 bacteriophage library consisting of 149,259 peptides tiling all protein-coding sequences from viruses with human hosts^{31,32}. Viral sequences were downloaded from Uniprot, collapsed on 552 90% identity, and bioinformatically parsed into 90 amino-acid peptide tiles with 45 amino-acid 553 554 overlaps between adjacent tiles. Healthy and Covid patients' plasma or serum and matched MENSA reactivities were profiled using phage immunoprecipitation and sequencing (PhIP-seq). 555 MENSA samples were profiled in duplicate and plasma/serum samples in triplicate. PhIP-seq 556 was performed as previously described with some modifications³². T7 bacteriophage libraries 557

were aliquoted into 96-well plates and incubated with 20µl each of protein A and G Dynabeads 558 559 on a rotator for 4 h at room temperature. Next, plates were placed on a magnet and supernatants were transferred to a fresh 96-well plate, to which we added patient plasma 560 containing 2µg of total IgG, and continued with the immunoprecipitation and washing steps, as 561 562 previously described. Following the washes, protein A and protein G Dynabeads were resuspended in PCR master mix, amplified with 16 rounds of PCR, SPRI cleaned to remove 563 564 primers, and indexed for sequencing with 8 rounds of PCR with primers containing Illumina p5 and p7 barcodes. NGS libraries were quantified on a Tapestation4200 and normalized for 565 566 sequencing on Illumina Nextseq 2000 or Novaseq 6000 instruments. Each sequencing library 567 received a minimum of 3M reads.

568

569 PhIP-seq single-end DNA sequences were aligned to a library of reference DNA sequences 570 (149,259 75bp for viral) with the bowtie2 aligner (v2.0) using end-to-end matching. Read counts 571 were summarized using samtools (v1.14) and collated into a counts matrix. The raw counts 572 were converted to counts per million (CPM) using the `cpm` function from the R package edgeR 573 (v3.36.0). CPM values for healthy controls were summarized by computing the peptide-wise 574 mean and standard deviation across all healthy control samples. CPM values for each patient 575 sample were collapsed by computing the peptide-wise minimum across technical replicates. 576 Paptide wise 7 secret were then computed as:

576 Peptide-wise z-scores were then computed as:

$$Z_{i,j} = \frac{\left(C_{i,j} - \mu_j\right)}{\sigma_i}$$

where $Z_{i,j}$ is the z-score for patient *i*, peptide *j*; $C_{i,j}$ is the minimum CPM for patient *i*, peptide *j*; μ_j is the mean of peptide *j* in the healthy control samples, and σ_j is the standard deviation of peptide *j* in the healthy control samples. For each patient, hits were identified as those peptides with $C_{i,j} \ge 10$ AND $Z_{i,j} \ge 10$.

581

582 Data Analysis:

All graphs were designed using GraphPad Prism, Excel, R studio, BioRender, and/or Adobe Photoshop. Comparisons among and between groups in figures 1,2,5 and supplemental figures 1 and 2 were calculated by Kruskal-Wallis tests, Mann-Whitney tests, and/or receiver-operating characteristic (ROC) curves using GraphPad Prism. To avoid overrepresentation of negative values on log scales, all values less than 10 Net MFI were replaced with 10 for figures 1-3 and 5. All calculations and statistics were performed using real values.

Table 1. Demographics of Controls, COVID-19 patients, and Vaccinated Subjects.
 590

Subjects	Healthy Adults	SARS2 Infection		Vaccinated	Post-SARS Infection	
		Mild/Moderate	Severe/Critical	Pfizer & Moderna	PASC	COVID Recovered
	N = 60	N = 54	N = 56	N = 11	N = 61	N = 25
Age, years						
(Mean ± SD)	(30 ± 9)	(40 ± 14)	(56 ± 14)	(40 ± 16)	(49 ± 12)	(41 ± 15)
Sex , N (%)						
Males	31 (52)	18 (33)	30 (54)	2 (18)	15 (25)	7 (28)
Females	29 (48)	36 (67)	26 (46)	9 (82)	46 (75)	18 (72)
Race, N (%)						
Caucasian	41 (68)	30 (56)	17 (30)	3 (27)	24 (39)	11 (44)
African American	4 (7)	17 (31)	35 (63)	3 (27)	34 (56)	9 (36)
Asian	10 (17)	4 (7)	4 (7)	5 (45)	2 (3)	3 (12)
Other	5 (8)	3 (6)	0 (0)	0 (0)	1 (2)	2 (8)

591

592 **Figures**:



593 594

595 Figure 1. Primary wild type COVID-19 infection responses in MENSA and serum. Dot plots show IgG antibody reactivity against S1-RBD in the MENSA (A) and serum (B) of patients 596 experiencing Wild Type SAR-CoV-2 infections in 2020. Similar results are also shown for anti-597 598 Nucleocapsid IgG in the MENSA (C) and serum (D). Samples from patients with acute Mild/Moderate (59 samples from 54 patients; blue dots) and Severe/Critical (60 samples from 56 599 patients; red dots) infections were collected less than 30 DPSO (acute) and/or after 60 DPSO 600 601 (convalescence). Early pandemic healthy controls, with no prior exposure to SARS2 (n=60), are shown as black dots on the left of each panel. All units are represented as Median Fluorescent 602 Intensity minus background (Net MFI). Dashed lines indicate the C₀ threshold of positivity for 603 604 each sample type and antigen. Serum C₀s were calculated as the average Net MFI plus five standard deviations of the 60 healthy controls (RBD: 1724; N: 682). For MENSA C0s, a subset 605 of the convalescent patients was identified as a confirmed COVID Recovered (CR) population 606 607 (no sequelae: N=19) and was used as a contemporary control group to calculate the average Net MFI plus 3 standard deviations (RBD: 570; N: 441). Pair-wise comparisons were performed 608 using the Kruskal-Wallis test in GraphPad Prism (unpaired, nonparametric test; ns p > 0.05, * p 609 610 ≤ 0.05 , ** p ≤ 0.01 , *** p ≤ 0.001 , **** p ≤ 0.0001).



611

Figure 2. Primary vaccination responses in MENSA and serum. Dot plots show IgG 612 antibody reactivity against S1-RBD in the MENSA (A) and serum (B) of subjects receiving their 613 primary COVID-19 mRNA vaccination, with no prior infection. Similar results are also shown for 614 anti-nucleocapsid IgG in the MENSA (C) and serum (D). Samples were collected from 11 615 healthy adults prior to vaccination (Baseline; n=7), after Dose 1 Peak (9-20 DPV; n=8), Dose 2 616 Peak (6-12 DPV; n=8), Dose 3 Baseline (>80 DPV dose 2 through 0 DPV dose 3; n=6), and 617 Dose 3 Peak (4-12 DPV dose 3; n=7). All values are reported as average Net MFI (Median 618 Fluorescent Intensity – Background). Dashed lines indicate the C₀ threshold of positivity for 619 each sample type and antigen as determined in Figure 1. Pair-wise comparisons were 620 performed using the Kruskal-Wallis test in GraphPad Prism (unpaired, nonparametric test; ns p 621 $> 0.05, * p \le 0.05, ** p \le 0.01, *** p \le 0.001, **** p \le 0.0001)$ 622



623

Figure 3. Kinetics of MENSA and serum after SARS2 infection and multiple vaccine

624 doses. Line graphs show MENSA (dark blue) and serum (light blue) IgG antibody responses to 625 S1-RBD (A,B) and Nucleocapsid (C,D) over time for a single patient starting with an initial 626

primary SARS2 infection in 2020, through three doses of Pfizer COVID-19 mRNA vaccination in 627

628 2021, and a breakthrough Omicron infection in 2022. All values are reported as average Net MFI (Median Fluorescent Intensity - Background). Red vertical dashed lines represent a new 629

exposure event. The primary and breakthrough infection events are symbolized as virions. Each 630

vaccination dose event is symbolized as a syringe. Horizontal dashed black lines represent the 631

C₀ threshold of positivity for each sample and antigen combination as determined from Figure 1. 632



633

Figure 4. Percentage of PASC patients with symptoms. Sixty PASC patients recruited in the 634 Emory Long-COVID clinic with self-reported symptom questionnaires at enrollment. 635

Percentages of each symptom is shown to the right of each bar. The twelve-symptom PASC 636 scores based on Thaweethai et al JAMA 2023 are shown in black with point scores in 637

parentheses after each symptom. 638



639

Figure 5. Prolonged, elevated MENSA IgG responses for SARS2 in a subset of PASC

patients. Dot plots show MENSA and serum IgG antibody responses to S1-RBD (A,B) and 641 Nucleocapsid (C,D) in samples collected between 60-279 DPSO since initial COVID-19 Wild 642 Type infection from patients who completely recovered from their acute illness (CR: n=19) and 643 644 patients who suffer PASC (n=39). Blue dots represent a Mild/Moderate acute disease severity. Red dots represent a Severe/Critical acute disease severity. All values are reported as average 645 Net MFI (Median Fluorescent Intensity – Background). Dashed lines indicate the C₀ threshold of 646 647 positivity for each sample type and antigen combination as determined from Figure 1. Pair-wise comparisons were performed using the Mann-Whitney test in GraphPad Prism (unpaired, 648

649 nonparametric test; ns p > 0.05, * p \leq 0.05, ** p \leq 0.01, *** p \leq 0.001, **** p \leq 0.0001).



650

Figure 6. Phage immunoprecipitation sequencing (PhIP-Seq) analysis of MENSA of PASC
 and CR patients for discovery. PhIP-seq analysis determines the level of binding of antibodies
 to 149,259 peptides tiling all protein-coding sequences from viruses with human hosts in
 MENSA samples from three CR (left column) and 10 PASC patients (middle column). Data are
 presented as z-scores of the anti-viral antibodies detected. Each row represents a linear peptide
 of viruses that were differentially bound in PASC and CR groups. Color code identifies virus
 species (right column).



658

Figure 7. MENSA and serum in PASC, CR, and healthy adults for SARS2, EBV, CMV, and 659 HSV2. MENSA (A) and serum (B) samples were collected from healthy donors prior to SARS2 660 661 exposure (top), COVID recovered (middle), and PASC (bottom) patients, tested for IgG reactivity against SARS2, EBV, CMV, and HSV2 antigens, and presented in a heat map. Green 662 cells represent Net MFI values \geq the C₀ thresholds calculated for each sample type and antigen 663 combination, while white or grey cells represent values below the C₀. In MENSA, a C₀ was 664 calculated as the average Net MFI of 22/23 CR samples plus three standard deviations for each 665 antigen. Each SARS2 Serum C₀ was calculated as the average plus three standard deviations 666 of the 16 Healthy Donor samples collected prior to SARS2 exposure. For each of the remaining 667 viruses, three clinically confirmed negative serum samples were obtained as virus specific 668 669 negative controls and the average Net MFI plus three standard deviations were used to 670 calculate C_0 for each antigen.

671 **REFERENCES**

672		
673 674	1.	Omer, S.B., Malani, P. & Del Rio, C. The COVID-19 Pandemic in the US: A Clinical Update. <i>JAMA</i> 323 , 1767-1768 (2020).
675	2.	Organization, W.H. COVID-19 weekly epidemiological update, 29 December 2020. (2020).
676	3.	El Sahly, H.M., et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N
677		Engl J Med 385 , 1774-1785 (2021).
678	4.	Walsh, E.E., et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. The New
679		England journal of medicine 383 , 2439-2450 (2020).
680	5.	Kumar, S., Thambiraja, T.S., Karuppanan, K. & Subramaniam, G. Omicron and Delta variant of SARS-CoV-2:
681		A comparative computational study of spike protein. <i>J Med Virol</i> 94 , 1641-1649 (2022).
682	6.	Thaweethai, T., et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA
683		329 , 1934-1946 (2023).
684	7.	Post COVID-19 condition (Long COVID).
685	8.	Woodruff, M.C., et al. Chronic inflammation, neutrophil activity, and autoreactivity splits long COVID. Nat
686		Commun 14, 4201 (2023).
687 688	9.	Klein, J., <i>et al.</i> Distinguishing features of long COVID identified through immune profiling. <i>Nature</i> 623 , 139-148 (2023).
689	10.	Su, Y., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185, 881-895 e820
690		(2022).
691	11.	Wong, A.C., et al. Serotonin reduction in post-acute sequelae of viral infection. Cell 186, 4851-4867 e4820
692		(2023).
693	12.	Liew, F., et al. Large-scale phenotyping of patients with long COVID post-hospitalization reveals
694		mechanistic subtypes of disease. <i>Nat Immunol</i> 25 , 607-621 (2024).
695	13.	Cervia-Hasler, C., et al. Persistent complement dysregulation with signs of thromboinflammation in active
696		Long Covid. <i>Science</i> 383 , eadg7942 (2024).
697	14.	Swank, Z., et al. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is
698		Associated With Post-acute Coronavirus Disease 2019 Sequelae. Clin Infect Dis 76, e487-e490 (2023).
699	15.	Peluso, M.J., et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J
700		Clin Invest 133 (2023).
701	16.	Carter, M.J., Mitchell, R.M., Meyer Sauteur, P.M., Kelly, D.F. & Truck, J. The Antibody-Secreting Cell
702		Response to Infection: Kinetics and Clinical Applications. <i>Front Immunol</i> 8 , 630 (2017).
703	17.	Halliley, J.L., et al. Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in
704		Human Bone Marrow. <i>Immunity</i> 43 , 132-145 (2015).
705	18.	Lee, F.E., et al. Circulating human antibody-secreting cells during vaccinations and respiratory viral
706		infections are characterized by high specificity and lack of bystander effect. <i>J Immunol</i> 186 , 5514-5521
707		(2011).
708	19.	Oh, I., et al. Tracking Anti-Staphylococcus aureus Antibodies Produced In Vivo and Ex Vivo during Foot
709		Salvage Therapy for Diabetic Foot Infections Reveals Prognostic Insights and Evidence of Diversified
710		Humoral Immunity. Infect Immun 86 (2018).
711	20.	Lee, F.E., Falsey, A.R., Halliley, J.L., Sanz, I. & Walsh, E.E. Circulating antibody-secreting cells during acute
712		respiratory syncytial virus infection in adults. <i>J Infect Dis 202,</i> 1659-1666 (2010).
713	21.	Wrammert, J., <i>et al.</i> Broadly cross-reactive antibodies dominate the human B cell response against 2009
714		pandemic H1N1 influenza virus infection. <i>The Journal of experimental medicine</i> 208 , 181-193 (2011).
715	22.	Wrammert, J., <i>et al.</i> Rapid cloning of high-affinity human monoclonal antibodies against influenza virus.
716		Nature 453 , 667-671 (2008).
717	23.	Haddad, N.S., et al. Novel immunoassay for diagnosis of ongoing Clostridioides difficile infections using
718		serum and medium enriched for newly synthesized antibodies (MENSA). <i>J Immunol Methods</i> 492 , 112932
719		(2021).
720	24.	Haddad, N.S., et al. Detection of Newly Secreted Antibodies Predicts Non-recurrence in Primary
721		Clostridioides difficile Infection. <i>J Clin Microbiol</i> , jcm0220121 (2022).
722	25.	Kyu, S., et al. Diagnosis of Streptococcus pneumoniae infection using circulating antibody secreting cells.
723		PLoS One 16, e0259644 (2021).

724 725 726	26.	Muthukrishnan, G., <i>et al.</i> A Bioinformatic Approach to Utilize a Patient's Antibody-Secreting Cells against Staphylococcus aureus to Detect Challenging Musculoskeletal Infections. <i>Immunohorizons</i> 4 , 339-351 (2020).
727 728	27.	Haddad, N.S., <i>et al.</i> Circulating antibody-secreting cells are a biomarker for early diagnosis in patients with Lyme disease. <i>PloS one</i> 18 , e0293203 (2023).
729	28.	Panel, CT.G. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. (National Institutes of
730	Health,	2020).
731	29.	Haddad, N.S., et al. One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination
732		Responses. Immunohorizons 5, 322-335 (2021).
733 734	30.	Woodruff, M., et al. Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extrafollicular B cell activation. medRxiv (2020).
735	31.	Nakagawa, S. & Takahashi, M.U. gEVE: a genome-based endogenous viral element database provides
736		comprehensive viral protein-coding sequences in mammalian genomes. Database (Oxford) 2016(2016).
737 738	32.	Xu, G.J. <i>, et al.</i> Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. <i>Science</i> 348 , aaa0698 (2015).
739	33.	Nguyen, D.C., et al. Majority of human circulating IgG plasmablasts stop blasting in a cell-free pro-survival
740		culture. <i>Scientific reports</i> 14, 3616 (2024).
741	34.	Magri, G., et al. Human Secretory IgM Emerges from Plasma Cells Clonally Related to Gut Memory B Cells
742		and Targets Highly Diverse Commensals. <i>Immunity</i> 47 , 118-134 e118 (2017).
743	35.	Phad, G.E., et al. Clonal structure, stability and dynamics of human memory B cells and circulating
744		plasmablasts. <i>Nat Immunol</i> 23 , 1076-1085 (2022).
745	36.	Stein, S.R., et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature
746		612 , 758-763 (2022).
747 748	37.	Koren, I., <i>et al.</i> The Eukaryotic Proteome Is Shaped by E3 Ubiquitin Ligases Targeting C-Terminal Degrons. <i>Cell</i> 173 , 1622-1635 e1614 (2018).
749	38.	Larman, H.B., <i>et al.</i> Autoantigen discovery with a synthetic human peptidome. <i>Nat Biotechnol</i> 29 , 535-541
750	20	(2011).
751 752	39.	321-327 (2022).
753	40.	Bedran, D., Bedran, G. & Kote, S. A Comprehensive Review of Neurodegenerative Manifestations of SARS-
754		CoV-2. <i>Vaccines (Basel)</i> 12 (2024).
755	41.	Grant, R.A., et al. Prolonged exposure to lung-derived cytokines is associated with activation of microglia
756		in patients with COVID-19. JCl Insight 9 (2024).
757	42.	Rippee-Brooks, M.D., et al. Viral Infections, Are They a Trigger and Risk Factor of Alzheimer's Disease?
758	40	Pathogens 13(2024).
759	43.	Mizrahi, B., et al. Long covid outcomes at one year after mild SARS-Cov-2 infection: nationwide conort
760	4.4	study. <i>Bivij</i> 380 , e072529 (2023). Vie V. 8. Al Alu, 7. Biele and hunders of insident disk stee in lang COV/Dus schert study. <i>L</i> anast Disk stee
701	44.	The, Y. & AI-AIY, Z. Risks and burdens of incident diabetes in long COVID: a conort study. Lancet Diabetes
762	1E	Endocrinol 10, 511-521 (2022). Via V. V. E. Bawa B. & Al Aly, 7 Lang term cardiovascular autoamos of COVID 10. Nat Mod 29, E82 E00.
764	45.	(2022)
765	46	(2022). Chang B et al. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study
766	40.	<i>EClinicalMedicine</i> 56 101783 (2023)
767	47	Sved 11 <i>et al.</i> Incidence of immune-mediated inflammatory diseases following COVID-19 ⁻ a matched
768	ч 7 .	cohort study in UK primary care <i>BMC Med</i> 21 363 (2023)
769	48.	Tesch, E., et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort
770		study. <i>Clin Rheumatol</i> 42 , 2905-2914 (2023).
771	49.	Middeldorp, J.M. Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease. <i>Current</i>
772		topics in microbiology and immunology 391 , 289-323 (2015).
773	50.	Karsten, C.B., et al. Evolution of functional antibodies following acute Epstein-Barr virus infection. PLoS
774		pathogens 18 , e1010738 (2022).

- 51. Wiegers, A.K., Sticht, H., Winkler, T.H., Britt, W.J. & Mach, M. Identification of a neutralizing epitope
 within antigenic domain 5 of glycoprotein B of human cytomegalovirus. *Journal of virology* 89, 361-372
 (2015).
- 77852.Lilleri, D., et al. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to779gH/gL/pUL128-130-131 complex during primary infection. PloS one 8, e59863 (2013).
- 53. Macagno, A., *et al.* Isolation of human monoclonal antibodies that potently neutralize human
 cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. *Journal of virology* 84, 1005-1013 (2010).
- 78354.Belshe, R.B., et al. Correlate of immune protection against HSV-1 genital disease in vaccinated women.784The Journal of infectious diseases 209, 828-836 (2014).